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CD81, a co-receptor for hepatitis C virus (HCV), is a member of the tetraspanin superfamily and is
heavily palmitoylated in the juxtamembrane cysteine residues. Palmitoylation plays an important role
in protein–protein interactions and association with cholesterol-rich domains of membranes. In this
study, Huh7 cells expressing wild-type or palmitoylation-defective CD81 were generated to analyze
whether palmitoylation of CD81 is involved in HCV cell entry. Our data showed that de-palmitoylation
of CD81 dramatically reduced its association with tetraspanin CD151, but did not inﬂuence CD81
partition in detergent-resistant membranes. Moreover, de-palmitoylated CD81 decreased the host cell
susceptibility to HCV. Notably, CD151-speciﬁc antibodies and siRNA inhibited HCV cell entry, and
detachment of CD81 with CD151 decreased the lateral movement of virus particle/CD81 complex to
areas of cell–cell contact. These results suggest that palmitoylation of CD81 should facilitate HCV entry,
at least in part, by regulating the association of CD81 with tetraspanin-enriched microdomains.
& 2012 Elsevier Inc. All rights reserved.Introduction
Approximately 180 million people are infected worldwide by
hepatitis C virus (HCV). A majority of those people are at risk for
the development of chronic infection, which induces end-stage
liver disease such as liver cirrhosis and hepatocellular carcinoma
(Lauer and Walker, 2001). However, treatment options for chronic
hepatitis C are limited and a vaccine is not available. Due to the
serious consequences of its infection in humans, much effort has
being made to understand the basic mechanisms of HCV cell entry
and infectivity.
HCV cell entry is a multi-step process mediated by several
receptors, involving scavenger receptor class B type I (SR-BI),
tetraspanin CD81, and tight junction proteins claudin-1 (CLDN1)
and occludin (OCLN) (Stamataki et al., 2008). CD81 is a member of
the tetraspanin superfamily deﬁned by four transmembrane
domains, a conserved CCG motif, and four cysteine residues that
form critical disulﬁde bonds in the large extracellular loop (LEL).
CD81 interacts with HCV envelope (E2) glycoprotein via a series
of discontinuous amino acid residues in LEL (Flint et al., 2006).ll rights reserved.
t@smmu.edu.cn (Z.-T. Qi).
.Antibodies directed against CD81 as well as a soluble form of the
CD81 LEL, are able to inhibit HCV entry into hepatocytes both
in vitro (Bartosch et al., 2003; Molina et al., 2008) and in vivo
(Meuleman et al., 2008). In conjunction with viral entry, a role for
CD81 in post-binding steps of HCV infection has been demon-
strated. Following virus binding, CD81-mediated signals allow the
lateral movement of virus particle/CD81 complex and its delivery
to areas of cell–cell contact (Brazzoli et al., 2008), which may
initiate viral internalization process (Harris et al., 2010).
Tetraspanins associate with tetraspanin and non-tetraspanin
proteins to many biological functions, including cell–cell adhesion,
cell migration, signaling and proliferation (Hemler, 2008). These
associations are thought to occur mainly in membrane compart-
ments such as lipid rafts and constitute tetraspanin-enriched micro-
domains (TEMs). In most cell lines, CD81 is associated in a high
stoichiometry with its partner proteins EWI-F or EWI-2 (Charrin
et al., 2003). Both are members of the EWI family, a small Ig-domain
family whose members have a single transmembrane domain and
several extracellular Ig-domains, as well as a very short cytosolic tail
(Stipp et al., 2001). Recently, it was shown that a truncated form of
its partner EWI-2 (EWI-2wint) blocked HCV infection (Rocha-
Perugini et al., 2008). This inhibitory effect depends on the interac-
tion of EWI-2/EWI-2wint with CD81 (Montpellier et al., 2011). In
addition to their direct and robust interaction with partner proteins,
tetraspanins also associate with each other dynamically and less
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CD151 and some other tetraspanins (Rocha-Perugini et al., 2009).
However, it is not known whether these interactions play a role in
HCV infection.
Palmitoylation occurs at the eight juxtamembrane cysteine
residues of CD81 (Delandre et al., 2009). Covalent attachment of
palmitate is a post-translational modiﬁcation that inﬂuences
protein–protein interactions and association with cholesterol-rich
domains of membranes (Linder and Deschenes, 2003). The palmi-
toylation of the juxtamembrane cysteine residues is present
in many tetraspanins, including CD9, CD63, CD81 and CD151
(Charrin et al., 2002). Mutagenesis of these cysteines, for example,
abolished the palmitoylation of CD9 (Kovalenko et al., 2004) and
of CD151 (Berditchevski et al., 2002), thus reducing their associa-
tion with other tetraspanins.
Tetraspanins are mainly present in part in a detergent-resistant
membrane (DRM) domain. These DRM are reported to be highly
ordered cholesterol-enriched microdomains, also termed lipid rafts.
These ordered membrane microdomains play an important role in
the early steps of virus infection by providing a convenient platform
for virus–receptor interactions (Lu et al., 2008; Carter et al., 2009;
Medigeshi et al., 2008). Targeting of proteins such as src kinases
(Dunphy and Linder, 1998), inﬂuenza hemagglutinin (Scheiffele
et al., 1997) and caveolin (Uittenbogaard and Smart, 2000) to lipid
rafts is dependent on palmitoylation. However, whether palmitoyla-
tion alters the association of CD81 with TEMs, and location of CD81
in lipid rafts, and whether these interactions play a role in CD81
mediating HCV cell entry remains to be addressed.
In this study, wild-type, partially or completely palmitoyla-
tion-defective CD81 were expressed in CD81-deﬁcient Huh7
hepatoma cells. These cells permitted an examination of the
effect of palmitoylation on the interaction of CD81 with TEMs
and their role in mediating HCV entry. The data suggest that
palmitoylation of CD81 strongly promotes HCV entry, at least in
part by regulating the association of CD81 with tetraspanin-
enriched microdomains.Results
Association of CD81 with CD151 is dependent on palmitoylation
To examine the role of palmitoylation in the intermolecular
association involving CD81, Huh7 cells were incubated with
2-bromopalmitate (2-BP), which is a potent inhibitor of palmi-
toylation. As shown in Fig. 1A, 2-BP treatment completely
eliminated the incorporation of [3H] palmitate into CD81. When
total CD81 content was assayed, a faster migrating band was
observed on polyacrylamide gels, which was consistent with the
loss of palmitoyl moieties (Fig. 1A). Additional co-immunopreci-
pitations showed that the levels of CD81-associated CD151 and
EWI-2 decreased by almost 95% and 10%, respectively, in 2-BP
treated compared to untreated cells (Fig. 1A).
To further demonstrate the role of CD81 palmitoylation in
protein–protein interactions, experiments were designed to examine
the interactions of palmitoylation-deﬁcient CD81 with CD151 and
EWI-2. For transmembrane proteins, palmitoylation typically occurs
on intracellular cysteine residues and proximal to transmembrane
domains (Resh, 1999). CD81 contains eight juxtamembrane cysteines
at position 6, 9, 80, 89, 97, 104, 227 and 228 (Fig. 1B). To evaluate the
contribution of palmitoylation to HCV infectivity, CD81-deﬁcient
Huh7 cells were stably transfected with wild-type CD81 (wtCD81)
or each of three cysteine mutants of CD81. Preliminary characteriza-
tion of these proteins showed comparable levels of expression
by FACS analysis (Fig. 1C). Importantly, CD81m5 incorporated only
about 30% of [3H] palmitate compared to wild type CD81, whileCD81m8 incorporated only about 10% of [3H] palmitate (Fig. 1C).
These observations conﬁrm that intracellular juxtamembrane
cysteine residues, proximal to all four TM domains, are palmitoylated
in CD81.
The effect of cysteine mutagenesis on associations of CD81
with other tetraspanin web members was analyzed by immuno-
precipitation under experimental conditions that maintain
tetraspanin–tetraspanin interactions (e.g. in 1% Brij97). As shown
in Fig. 1D, the amount of CD81 co-immunoprecipitated with
endogenous CD151 depended on the number of cysteines in the
intracellular and transmembrane domains. Elimination of palmi-
toylation (CD81m8) almost completely abolished the interaction
of CD81 with tetraspanin CD151 (Fig. 1D, upper panel), and
slightly reduced the association with its partner, EWI-2 (Fig. 1D,
lower panel). Hence, these data suggest that the mutation of
juxtamembrane cysteine residues affects the association of CD81
with tetraspanin CD151.
Palmitoylation does not contribute to raft localization of CD81
Since palmitoylation promotes the association of most trans-
membrane proteins with lipid rafts (Dunphy and Linder, 1998;
Scheiffele et al., 1997; Uittenbogaard and Smart, 2000), experi-
ments were designed to investigate whether palmitoylation of
CD81 played a role in its partition to DRM. Brij97 lysates of Huh7
cells expressing wild type or mutant CD81 were subjected to
density equilibrium centrifugation in sucrose gradients, and the
fractions then analyzed by western blotting. As shown in Fig. 2A,
wtCD81 appeared in the low density fractions of a sucrose
gradient. There was no difference in the distribution of wtCD81
and palmitoylation-deﬁcient CD81, indicating that mutation of
juxtamembrane cysteines did not change the ﬂotation properties
of CD81 (Fig. 2A). In control experiments, abundant endogenous
caveolin-2 was in the low density fractions (Fig. 2A, Fractions
3–5) and CD71 marked the dense fractions (Fig. 2A, Fractions 9–12).
To further dissect the contribution of palmitoylation to CD81 raft
localization, lysates from 2-BP-treated and untreated Huh7 cells
were subjected to sucrose density gradient centrifugation. After
pharmacological block of palmitoylation, wild-type CD81 exhibited
similar distribution with sucrose gradients to their palmitoylation-
deﬁcient counterparts (Fig. 2B, upper panel). In contrast, 2-BP
treatment shifted the distribution of caveolin-2 into the heavier
fractions of the sucrose gradient (Fig. 2B, bottom panel).
To verify that the western blotting data reﬂected plasma
membrane localization of CD81 mutants, confocal laser scanning
microscopy was performed using antibodies against CD81 and
caveolin-2. As shown in Fig. 2C, wtCD81 and CD81 mutants co-
localized with caveolin-2. Taken together, these results show that
blocking of palmitoylation does not have a signiﬁcant inﬂuence
on the raft localization of CD81.
Mutation of juxtamembrane cysteines in CD81 impairs HCV entry
To determine whether palmitoylation of CD81 alters its func-
tion as a HCV receptor, each CD81 mutant was analyzed for its
capacity to mediate HCV-E2 binding, HCVpp entry and HCVcc
infection. To test the capacity of these CD81 variants to interact
with HCV glycoproteins, we used a soluble recombinant form of
HCV E2 glycoprotein (sE2). As shown in Fig. 3A, sE2 bound to
wtCD81 and to all CD81 mutants to similar extents, suggesting
that removal of the palmitoylation does not affect binding of
CD81 to the HCV envelope.
To examine the effect of CD81 palmitoylation on viral entry,
Huh7 cells expressing wild type or mutant CD81 were infected
with pseudotyped particles bearing HCV envelope proteins of
different genotypes or VSV-G envelopes as control. Compared to
Fig. 1. Association of the palmitoylation-deﬁcient CD81 with CD151 and EWI-2. (A) Huh7 cells were preincubated with 25 mM 2-BP or DMSO for 24 h and then labeled for
2 h with [3H] palmitic acid in the continued presence of 2-BP or DMSO. Cells were lysed in a buffer containing 1% Brij97 and immunoprecipitated using anti-CD81 mAb.
Following SDS-PAGE and transfer to PVDF membranes, the immunoprecipitated complexes were exposed to autoradiography (upper panel) and probed with mAb for
detection of CD81, CD151 and EWI-2 (lower panels). (B) Schematic representation of CD81 with indication of the juxtamembrane cysteine residues, and their change in the
mutant molecules. The numbers indicated correspond to the position of cysteines in the CD81 sequence. C and D, Huh7 cells expressing wtCD81 or CD81 mutants were
labeled with [3H] palmitic acid. Cells were lysed and immunoprecipitations were performed. (C) Cell lysates were immunoprecipitated with anti-CD81 mAb. The extent of
[3H] palmitate labeling was determined by autoradiography (upper panel). A fraction of the immunoprecipitates was analyzed by immunoblotting using anti-CD81 mAb
(middle panel). Surface CD81 expression was analyzed by ﬂow cytometry using 5A6 (lower panel). Results are reported as the mean7SD of three independent
experiments. (D) Cell lysates were immunoprecipitated with anti-CD151 or anti- EWI-2 mAb. The immunoprecipitates was analyzed by immunoblotting for the detection
of CD81, CD151 and EWI-2. The results of a representative of three experiments are shown.
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about 75% that of cells expressing wtCD81, and for CD81m6
expressing cells, entry was reduced to 54% (Fig. 3B). When all eight
cysteine residues in the juxtamembrane domain of CD81 were
mutated to alanine, entry was reduced to 40%, but the infectivity
of VSV pseudovirus was not altered signiﬁcantly (Fig. 3B, VSV-G).
Additional work was conducted to evaluate the infectivity of
HCVcc in Huh7 cells expressing wild type or individual mutant CD81
molecules. Again, Huh7 cells expressing CD81m8 reduced their
infectivity to about 48% compared to Huh7 cells (Fig. 3C), which is
similar to the assays above using HCVpp, suggesting that palmitoyla-
tion of CD81 contributes to viral entry during HCV infection.
siRNA and antibody speciﬁc for CD151 inhibit HCV entry
The above work supports the hypothesis that CD81 palmitoyla-
tion contributes importantly to mediating HCV entry in association
with TEMs. In this context, the ﬁndings that CD81 and CD9 are
closely related tetraspanins (Hemler, 2001), and that CD151 stronglybinds to CD81 (Rocha-Perugini et al., 2009), imply that CD9may also
potentially play a role in HCV infection. When this was evaluated,
the data showed low surface expression of CD9 in the presence of
high expression levels of CD151 in CD81 negative Huh7 cells (data
not shown), suggesting CD9 may not be operative.
To evaluate the role of CD151 upon infectivity, CD151 levels
were depleted by siRNA treatment, and then the cells were
challenged with HCV. Efﬁciency of siRNA-mediated knockdown
of CD151 on the cell surface was analyzed by FACS assay. As
shown in Fig. 4A, siRNA-1 reduced cell surface expression of
CD151 to 24% in Huh7 cells (mean intensity), while a second
CD151 speciﬁc siRNA (siRNA-2) showed similar results, reducing
CD151 expression to about 29% of wild type levels. Importantly,
infection of siCD151-treated cells by HCVpp and HCVcc was
markedly reduced, as compared to control siRNA-treated cells
(Fig. 4B and C). CD151-speciﬁc siRNAs reduced HCVpp entry of
different genotypes to approximately 35% (siRNA-1) or 46%
(siRNA-2) (Fig. 4B) and HCVcc infectivity to 41% (siRNA-1) or 49%
(siRNA-2) in Huh7 cells (Fig. 4C). These results suggest that CD151
Fig. 2. Raft localization of the unpalmitoylated CD81 in Huh7 cells. (A) Huh7 cells expressing wtCD81 or CD81m8 were lysed with Brij97 and subjected to sucrose density
grandient centrifugation. Gradient fractions were collected and analyzed by immunoblotting using the anti-CD81, caveolin-2 or CD71 antibody. The fractions are indicated
at the top of each lane. (B) Huh7 cells preincubated with 25 mM 2-BP or DMSO for 24 h, and then subjected to sucrose gradient fractionation as described in the legend to A.
The results of a representative of three experiments are shown. (C) Huh7 cells expressing wtCD81 or CD81m8 were cultured on the slides for 24 h. Cells were incubated
with the mouse anti-CD81 antibody (5A6) and rabbit anti-caveolin-2 antibody for 1 h at 4 1C, followed by Alexa Flour 488-conjugated anti-mouse and Alexa Flour
555-conjugated anti-rabbit antibody for 1 h at 4 1C. Representative results are shown. The colocalization of red and green gives yellow staining. Bars, 10 mm.
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virus subtype.
Since siRNA-inhibition studies suggested that the tetraspanin
CD151 is primarily involved in HCV infection, additional work
was performed to determine whether pretreatment of Huh7 cells
with CD151 speciﬁc antibody might inhibit infection. As shown in
Fig. 4D, the anti-CD151antibody inhibited HCV entry into Huh7 in
a dose-dependent manner. To further elucidate the entry steps
targeted by the anti-CD151 antibody, the kinetics of entry were
evaluated (Krieger et al., 2010) (Fig. 4E). Heparin, a well-char-
acterized molecule shown to interfere with HCV infection pre-
dominantly during viral attachment (Barth et al., 2006; Zeisel
et al., 2007), markedly blocked HCVcc infection when added prior
to HCVcc binding, but inhibited HCVcc infection less efﬁciently
when added post-binding (Fig. 4F). Similar to concanamycin A
(an inhibitor of endosomal acidiﬁcation), the anti-CD151 had aninhibitory effect when added at 60–90 min after infection. Taken
together, these data suggest that CD151 is involved in HCV cell
entry by modulating early and late steps of post-binding events.
Relocalization of HCV glycoproteins to tight junction protein, claudin-
1, is affected by depalmitoylation of CD81 or by siCD151 treatment
Post-binding steps of HCV entry are mediated by the HCV
entry factors SR-BI, CD81, CLDN1 and OCLN. To understand the
mechanistic role of TEMs, experiments were designed to test
whether disruption of the CD81–TEMs associations alter expres-
sion of the above factors. Treatment of parental Huh7 cells with
siRNA targeting CD151 (Fig. 5A) or depalmitoylation of CD81
(data not shown) had no effect on HCV entry factor expression.
After the virus attachment, HCV bound to the surface of hepato-
cytes can be transported laterally to areas of cell–cell contact
Fig. 3. Role of CD81 palmitoylation in HCV entry. (A) E2 binding activity of CD81 mutants was determined using soluble E2 protein (sE2). The results of sE2 binding were
expressed as the mean percentages of mean ﬂuorescence intensity detected in wtCD81 or CD81 mutant-expressing Huh7 cells which were incubated with sE2. The value of
wtCD81 was set as 100%. Results are reported as the mean7SD of three independent experiments. (B and C) Effect of CD81 mutations on HCVpp entry and HCVcc
infectivity. Huh7 cells expressing wtCD81 and CD81 mutants were infected with HCVpp of different genotypes or HCVcc of JFH-1 strain. (B) The results were expressed as
percentages of infectivity relative to infectivity of HCVpp on cells expressing wtCD81. Results are reported as the mean7SD of three independent experiments.
(C) Efﬁciency of HCVcc infection was determined as the percentage of HCV NS5A-positive cells relative to infectivity of HCVcc on cells expressing wtCD81. Results are
reported as the mean7SD of three independent experiments.
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mediated inhibition of HCVcc. (F) Time course of HCVcc infection of Huh7 cells after incubation with anti-CD151 mAb. Results are reported as the mean7SD of three
independent experiments.
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Y.-Z. Zhu et al. / Virology 429 (2012) 112–123118mediated solely by CD81, where it comes into contact with the co-
receptor claudin-1 (Brazzoli et al., 2008). We therefore used recom-
binant HCV E2 to examine the lateral migration of CD81-associated
tetraspanin. For this purpose, Huh7 cells were cultured on coverslips
overnight to achieve a conﬂuent layer and then stimulated with
soluble HCV E2 at 37 1C. At indicated time after the addition of sE2,
cells were ﬁxed and stained with speciﬁc antibodies. Indeed, while
CD81 and cell-bound HCV E2 were detected in a diffuse pattern along
the whole cellular surface at 10 min, after 60 min of engagement at
37 1C, they concentrated at areas of cell–cell contact (Fig. 5B). A
similar relocalization of CD151 was observed (Fig. 5B), indicating the
involvement of CD151 in the lateral movement of HCV E2.
Next, similar experiments were designed to test whether the
association of CD81 with TEMs interfered with the relocalization
of virus to CLDN1 using confocal microscopy. In Huh7-wtCD81
cells, cell-bound E2 accumulated at areas of cell–cell contact after0
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Fig. 5. Effect of depalmitoylation of CD81 or siCD151 treatment on the lateral moveme
cells, as assessed by ﬂow cytometry. Results are reported as the mean7SD of three ind
soluble HCV E2 glycoprotein for indicated minutes at 37 1C. Cells were then ﬁxed and
mouse-Alexa Fluor 488 secondary antibody (green). Nuclei were stained with DAPI (blue
(CD81m8) were cultured on slides overnight to achieve a conﬂuent layer and then stim
with antibodies against HCV E2 and claudin-1, followed by an anti-rabbit-Alexa Fluor 55
(green), as indicated. Areas of colocalization appear yellow. Bars, 10 mm. (D) Soluble HC
and stained with antibodies against HCV E2 and claudin-1 as described in legend to C.
reader is referred to the web version of this article.)60 min of engagement at 37 1C, co-localizing with claudin-1
(Fig. 5C). However, on the membrane surface of cells expressing
CD81m8, relocation of E2 to CLDN1 was markedly decreased
(Fig. 5C). HCV E2 was detected in a diffuse pattern along the cell
surface (Fig. 5C). There was also reduced level of E2 accumulation
at the boundaries in siCD151-treated Huh7 cells, while the
majority of cell-bound E2 was delivered to CLDN1 in mock-
treated cells (Fig. 5D). These data suggest that the association of
CD81 with TEMs plays a role in mediating the relocalization of
virus to tight junction protein claudin-1.Discussion
HCV cell entry involves a set of receptors. Among them, CD81
directly interacts with HCV envelope glycoprotein and alsoOCLN
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contact. CD81 belongs to the tetraspanin superfamily, members of
which interact with each other to participate in various biological
roles. The work herein set out to characterize the essential require-
ments of CD81 palmitoylation for its association with TEMs and
HCV entry.
To generate palmitoylation-deﬁcient CD81 proteins, Bertaux
and his colleagues mutated ﬁve cysteines located in the intracel-
lular domains of CD81 (Bertaux and Dragic, 2006). However,
the predicted three-dimensional conformation of CD81 showed
another three cysteines at the transmembrane domains where it
would be available for palmitoylation (Seigneuret, 2006). In this
study, we constructed the mutants for all of the related eight
cysteines to alanines to eliminate palmitoylation. Palmitoylation of
tetraspanins affects protein–protein interactions, suggesting a key
role in the assembly of the tetraspanin web. Co-immunoprecipita-
tions of CD81 mutants showed that the association of CD81 with
endogenous CD151 correlated with the level of palmitoylation. The
ﬁnding that 2-BP prevented CD81–tetraspanin interactions further
supported the important role of palmitoylation for the association
of CD81 with TEMs. TEMs protein associations can be divided into
three categories. In the ﬁrst category (Level 1), each tetraspanin
forms primary complexes with a limited number of molecular
partners, which are stable in Triton X-100, and are likely to bedirect, such as with CD81/EWI-2 (Charrin et al., 2001) and CD151/
a3b1 complex (Yauch et al., 2000). Most tetraspanin–tetraspanin
associations (such as CD9, CD63, CD81, CD151), formed between
members of the family, are Level 2 interactions (Lozahic et al.,
2000). These secondary associations can be disrupted by Triton
X-100 but are retained in Brij97 or other less hydrophobic deter-
gents (Boucheix and Rubinstein, 2001). Tetraspanins associate
indirectly with additional proteins, which have been referred to
Level 3 interactions. These complexes are not disrupted in milder
detergents, such as 1% CHAPS. These include tetraspanin associa-
tions with various signaling molecules and cytoskeletal structures
(Shi et al., 2000; Levy and Shoham, 2005). Our results showed that
EWI-2 interaction with unpalmitoylated CD81 was only slightly
decreased. One possibility is that other domains of CD81, such as LEL
(Shoham et al., 2006), could also be involved in its association with
partner proteins. Importantly, the interaction between CD81 and
EWI-2 has been proposed to be independent of CD81 palmitoylation
(Montpellier et al., 2011). However, in the latter study, only six of
eight potential cysteines were mutated. Together these results
suggest that the maintenance of tetraspanin–tetraspanin interac-
tions is generally regulated by palmitoylation.
Since palmitoylation is important for many transmembrane
proteins partitioning into lipid rafts, we detected the requirement
of palmitoylation for the raft localization of CD81. The results
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not signiﬁcantly affect the location of CD81 in DRM. In support of
this, treatment of 2-BP yields in a shift of caveolin-2 to non-raft
domains but does not shift the raft localization of CD81. Con-
sistent with the results herein, depalmitoylation of multiple
members of the tetraspanin family including CD9 (Charrin et al.,
2002), CD151 (Berditchevski et al., 2002), and CD63 (Israels and
McMillan-Ward, 2010) is insufﬁcient to promote them partition-
ing to non-raft regions. These data indicate that the role of
tetraspanin palmitoylation in maintenance of TEMs is distinct
from that of raft localization.
Compared with wtCD81, palmitoylation-deﬁcient CD81
mutants exhibited similar sE2 binding, but markedly reduced
the susceptibility of Huh7 cells to HCV. This inhibition probably
occurs at cell entry steps, since CD81 mutants impair the infection
of single-cycle HCV pseudoparticles of diverse genotypes. CD81
partitioning in lipid raft is important for HCV entry (Kapadia et al.,
2007). As mutation of palmitoylation sites has no signiﬁcant
impact on the raft localization of CD81, it is hypothesized that
the unpalmitoylated CD81 mediated reduced HCV entry by
affecting its association with TEMs. Besides the tetraspanin–
tetraspanin interaction, the direct interaction between tetraspa-
nins and their partner proteins also results in the modulation of
their functions. CD81 functions in infectious diseases can there-
fore be affected by the association with the proteins EWI-F, EWI-2
or EWI-2wint. EWI-F acts as a negative regulator of Plasmodium
yoelii infection by interacting with CD81 and regulating its
function (Charrin et al., 2009). EWI-2wint, a cleavage product of
EWI-2, needs to interact with CD81 to exert its inhibitory effect on
HCV infection (Rocha-Perugini et al., 2008). However, about 60%
reduction of HCV entry seems not to be fully explained by only 10%
detachment of EWI-2 with depalmitoylated CD81. Therefore, it is
hypothesized that the interaction of CD81 with other tetraspanins
could beneﬁt HCV infection. As expected, siRNA-mediated knock-
down or speciﬁc antibody targeting CD151 exert a strong inhibitory
effect on HCV entry. Furthermore, treatment of the cells with anti-
CD151 antibody inhibited HCV infection at late steps of HCV entry.
Applying confocal microscopy, it was shown that CD151 played a
functional role in the relocalization of HCV E2/CD81 complex to
areas of cell–cell contact.
After virus binding, CD81 triggered Rho-GTPase-dependent
actin rearrangement that allows the delivery of virus–receptor
complex to areas of cell–cell contact (Brazzoli et al., 2008). In this
context, the study herein provides preliminary data showing that
depalmitoylation of CD81 or treatment of the cells with CD151
speciﬁc siRNA reduced the relocalization of HCV E2/CD81 complex
to tight junction protein CLDN1. Data from the present work
extend recent observations that TEMs involved in the infection
process of various viruses, such as HIV (Gordon-Alonso et al.,
2006), HTLV-1 (Pique et al., 2000), HPV (Spoden et al., 2008),
although tetraspanins are not receptors for these viruses. The
association of CD81 with TEMs may facilitate the signaling path-
ways that permit the uptake of the active entry complex efﬁciently,
which is consistent the role of tetraspanins in providing speciﬁc
functional links to cytoskeletal or signaling proteins (Stipp et al.,
2001; Yunta and Lazo, 2003; Levy and Shoham, 2005; Sala-Valdes
et al., 2006). A recent study has showed that in chronic hepatitis C
(CHC)-infected liver tissues, CD151 was found in the E2-immuno-
precipitated complexes (Sanz-Cameno et al., 2008), suggesting that
virions may preferentially interact with CD81-associated TEMs.
The ﬁnding that anti-CD151 antibody mainly recognizes the LEL,
implies that the extracellular domains of both tetraspanins are also
involved in their association. CD151 antibody could impair the
interaction between the extracellular domains of both tetraspanins
by steric hindrance, resulting in decrease the signaling pathways
and redistribution of HCV/CD81 complexes.Recently, Vera et al. took advantage of a monoclonal antibody
that speciﬁcally recognizes a subset of mouse CD81 molecules
associated with TEMs (MT81w) to investigate the role of TEM-
associated CD81 in HCV infection. In contrast to the present study,
these investigators found that TEMs-associated CD81 is not
essential for viral entry. The observed discrepancy may be due
to the species-speciﬁc CD81 used. A number of experiments have
demonstrated the failure of mouse CD81 to mediate HCV entry
(Flint et al., 2006; Ploss et al., 2009). Among the HCV receptors,
CD81 and OCLN represent the minimal human-speciﬁc entry
factor (Ploss et al., 2009). The inhibitory effect of the antibody
targeting TEMs-associated CD81 on HCV infectivity may yield a
negative result by using the mouse CD81 model. Besides the
different species of CD81, It is also possible that the lower afﬁnity
of MT81w may lead to an underestimate of the ratio of CD81
engaged in TEMs (Silvie et al., 2006).
In conclusion, this study demonstrates the important role of
CD81 palmitoylation in association with TEMs and mediating HCV
cell entry. These ﬁndings provide novel insights into understand-
ing of the very early steps of HCV infection and the development
of novel antiviral strategies targeting viral entry.Materials and methods
Cells and antibodies
CD81-deﬁcient Huh7 hepatoma cells (Huh7 CD81) were pro-
vided by Jin Zhong (Institut Pasteur of Shanghai, Chinese Academy
of Sciences, Shanghai, China) (Zhong et al., 2006). Huh7 and HEK
293T cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum (Invitrogen). CD81
(5A6), anti-CD71 (3B8 2A1) and CD151 (11G5a) monoclonal anti-
bodies were purchased from Santa Cruz Biotechnology. Caveolin-2
antibody was purchased from Sigma. EWI-2 monoclonal antibody
(8A12) was a generous gift from Eric Rubinstein (INSERM U268,
Paris, France). Claudin-1 antibody was obtained from Invitrogen.
Horseradish peroxidase (HRP)-conjugated anti-mouse and anti-
rabbit Ig were purchased from Santa Cruz Biotechnology. Alexa
488 conjugated anti-mouse Ig and Alexa 555 conjugated anti-rabbit
Ig was purchased from Invitrogen.
Mutagenesis and transfection
The CD81 constructs with mutations in the juxtamembrane
cysteines (position 6, 9, 80, 89, 97, 104, 227, 228) were generated
by using fusion PCR, in which the cysteine residues were replaced
by alanines. Wild-type CD81 (wtCD81) and CD81 mutants were
inserted into pcDNA3.1 (þ) vector (Invitrogen), respectively. Each
of the resulting plasmids was veriﬁed by sequency and trans-
fected into CD81-deﬁcient Huh7 cells by using Lipofecatimane
2000 (Invitrogen).
Incorporation of [3H]-palmitate
For experiments using 2-Bromopalmitate (2-BP), cells were
pretreated with 25 mM 2-BP (Sigma) for 24 h. As a negative
control for 2-BP, cells were treated with 0.05% DMSO. Then 2-BP
and DMSO were removed, and the cells were washed three times
with PBS followed by metabolic labeling, immunoprecipitation
and lipid raft isolation as described below.
To assess palmitic acid incorporation, cells were serum starved
for 3 h and labeled overnight with 0.3 mCi/ml [3H] palmitic acid
(PerkinElmer Life Sciences) in DMEM supplemented with 5% fetal
bovine serum. Cells were harvested and washed three times with
PBS followed by lysis and immunoprecipitation with anti-CD81
Y.-Z. Zhu et al. / Virology 429 (2012) 112–123 121antibody 5A6 as described below. The samples were then separated
by non-reducing SDS-PAGE, transferred to PVDF membranes, and
membranes were exposed to Kodak BioMax MS Film (Eastman
Kodak Company, Rochester, NY) for one week at 80 1C.
Immunoprecipitation and immunoblotting
For immunoprecipitation, cells were prepared in lysis buffer
containing 1% Brij97 (Sigma), 25 mM HEPES, 150 mM NaCl, 5 mM
MgCl2, 20 mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mM phe-
nylmethylsulfonyl ﬂuoride. After 1 h at 4 1C, insoluble material
was pelleted at 16,000g (25 min, 4 1C). The supernatants were
treated by incubation with protein G-Sepharose (Roche Molecular
Biochemicals, Indianapolis, IN), and then incubated with speciﬁc
antibodies for 1 h at 4 1C, followed by overnight incubation with
protein G-Sepharose. Immune complexes were collected by cen-
trifugation, washed three times in lysis buffer, and then analyzed
by SDS-PAGE (12% acrylamide) under non-reducing conditions.
The proteins were transferred to PVDF membranes and probed
with primary antibody, then following with secondary antibody:
HRP-conjugated anti-rabbit or anti-mouse antibodies. Bound
antibodies were detected with the ECL Plus Western blotting
detection reagents (PerkinElmer Life Sciences). Bands from che-
miluminescence were quantitated using AlphaView 3.0 software
from NatureGene Corp.
Lipid raft isolation
Cells (5107) were washed twice with ice-cold PBS and lysed
on ice for 30 min in 1 ml TNE-buffer (25 mM Tris [pH 7.5],
150 mM NaCl, 5 mM EDTA, and complete protease inhibitor
cocktail (Roche)) with 1% Brij97. The cell lysates were homo-
genized and then centrifuged for 5 min, 1000g at 4 1C to remove
insoluble materials. The supernatant was mixed with 1 ml 80%
sucrose in TNE buffer, placed at the bottoms of ultracentrifuge
tubes, overlaid with 7 ml 30% and 3 ml 5% sucrose in TNE buffer.
The cell lysates were ultracentrifuged at 4 1C for 18 h at
36,000 rpm in a SW41 rotor (Beckman). After centrifugation,
twelve 1-ml fractions were collected from the top to the bottom
and analyzed immediately by immunoblotting.
About 20 ml of individual sucrose gradient fractions were
resolved by SDS-PAGE (12% acrylamide). Western blotting was
performed using caveolin-2, anti-CD71 and CD81 mAbs, with
horseradish peroxidase-conjugated secondary antibody. Blots
were visualized by chemiluminescence.
Production of HCVpp and infection assays
HCVpp were generated by the co-transfection of HEK 293T cells
with a HCV envelope protein expression vector and packaged
plasmid based on the HIV-1 strain NL4-3 (Invitrogen), as described
previously (Tong et al., 2011). Brieﬂy, 293T cells were co-transfected
with expression plasmids encoding the HCV envelope glycoproteins,
HIV gag/pol (pLP1), HIV rev (pLP2) and pLenti6 encoding luciferase.
HCV envelope expression plasmids used here included genotype 1a
strain H77 (provided by F.L. Cosset, INSERM U758, Lyon, France),
genotype 1b strain Con-1 (provided by C. M.Rice, Rockefeller
University, NY, USA) and genotypes 2a (clone UKN2A1.2), 2b (clone
UKN2B2.8), 3a (clone UKN3A1.28C), and 4a (clone UKN4.21.16)
(provided by J.K. Ball, The University of Nottingham, United King-
dom). Supernatants containing pseudotyped particles were har-
vested at 48 h post-transfection and ﬁltered through 0.45-mm
membranes, and used for infection. Vesicular stomatitis virus
glycoprotein (VSV-G) pp was prepared for use as a control. HCVpp
and VSV-Gpp were added to Huh-7 cells expressing wtCD81 or
CD81 mutants seeded the day before in 24-well plates andincubated for indicated times at 37 1C. The supernatants were then
removed, and the cells were incubated in DMEM with 3% FBS at
37 1C. At 72 h post infection, the cells were washed once in PBS then
lysed in 50 ml of lysis buffer (Promega). Luciferase activity was
quantiﬁed using the Bright Glow Luciferase Assay System (Promega).
Production of HCVcc and infection assays
The plasmid pJFH-1, containing the full-length cDNA of JFH-1
isolate and kindly provided by T. Wakita (National Institute of
Infectious Diseases, Tokyo, Japan), was used to generate HCVcc as
previously described (Wakita et al., 2005; Rouille´ et al., 2006).
Brieﬂy, the pJFH-1 plasmid was linearized and used as a template
for in vitro transcription with the MEGAscript kit from Ambion.
In vitro transcribed RNA was delivered to Huh-7 cells by electro-
poration, and viral stocks were obtained by harvesting cell culture
supernatants 1 week after transfection.
Huh7 cells expressing wtCD81 or CD81 mutants were infected
with HCVcc for 5 h at 37 1C. At 72 h postinfection, cells were ﬁxed,
permeabilized, and immunostained for NS5A protein using anti-
NS5A mAb 9E10 clone (provided by C.M. Rice, Rockefeller Uni-
versity, NY, USA). Infection was determined by enumerating
NS5A-positive cells or foci under a ﬂuorescence microscope as
previously described (Mee et al., 2009).
E2 binding assays
The soluble E2 (sE2) protein harboring six histidines at its
C-terminal was expressed in CHO cells that stably transfected
with plasmid containing truncated E2 sequence of H77 strain
(364–661 aa in HCV polyprotein), the protein was puriﬁed using a
nickel-chelating Sepharose resin (Qiagen) from culture super-
natants. Binding of soluble E2 glycoprotein, derived from the
H77-E2 was performed as previously described (Flint et al., 2000).
Huh7 cells (2105) expressing wtCD81 or CD81 mutants were
incubated with 5 mg/ml of sE2 for 1 h at room temperature in PBS
supplemented with 1% bovine serum albumin and were then
washed twice with PBS. Soluble E2 binding to cells was detected
by ﬂow cytometry (Beckman Coulter) after labeling with the anti-E2
mAb H53 (provided by J. Dubuisson, Institut Pasteur, Lille, France)
followed by an Alexa Flour 488-conjugated anti-mouse IgG.
Flow cytometry
To analyze cell surface expression of CD81, suspended cells
expressing wtCD81 or CD81 mutants were treated with anti-CD81
mAb (5A6) for 1 h at 4 1C. The cells were washed with PBS three
times, and then treated with an Alexa Flour 488-conjugated anti-
mouse IgG. The stained cells were applied to a ﬂow cytometry.
Confocal microscopy
Cells were cultured on eight-well culture slides (Millipore) at
37 1C in a humidiﬁed 5% CO2 atmosphere for 24 h and then
subjected to confocal microscopy analysis. Cells were incubated
with the mouse anti-CD81 mAb and rabbit anti-caveolin-2 antibody
for 1 h at 4 1C, followed by Alexa Flour 488-conjugated anti-mouse
and Alexa Flour 555-conjugated anti-rabbit Ig for 1 h at 4 1C.
In some experiments, Huh7 cells were incubated with soluble
HCV E2 protein (aa 364–661 of H77 strain) expressed by CHO
cells in this laboratory at a concentration of 10 mg/ml for the
indicated time at 37 1C. Cells were ﬁxed in 3% formaldehyde and
then probed with E2 mAb H53 or claudin-1 polyclonal antibody.
After the incubation with ﬂuorescence-conjugated secondary
antibodies, cells were observed using a confocal ﬂuorescence
microscope (Zeiss).
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The speciﬁc siRNAs targeting CD151, siCD151-1 (TCACAG-
GACTGGCGAGACATT) (Kovalenko et al., 2007) and CD151-2 (CAU-
GUGGCACCGUUUGCCUTT) (Spoden et al., 2008) were obtained from
Invitrogen. As control we used siCD151-1 speciﬁc siRNA with two
mismatches (TCACCGGACTGACGAGACATT). Huh7 cells were trans-
fected with 30 nM of siRNA using Lipofectamine RNAiMAX according
to the manufacturer’s instructions. Subsquent experiments were
done 72 h after siRNA transfection. Knockdown efﬁciencies were
quantiﬁed by ﬂow cytometry.Conﬂicts of interest
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